These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33044358)

  • 21. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
    Wang M; Xiong Z; Su B; Wang L; Li Z; Yang Y; Fang J; Li Z
    J Clin Pharm Ther; 2020 Feb; 45(1):199-203. PubMed ID: 31468568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
    Kang MJY; Vazquez GH
    J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Su TP
    Psychopharmacology (Berl); 2021 Mar; 238(3):857-865. PubMed ID: 33471146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New use for an old drug: oral ketamine for treatment-resistant depression.
    Swiatek KM; Jordan K; Coffman J
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
    De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
    Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
    Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
    Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
    [No Abstract]   [Full Text] [Related]  

  • 32. Ketamine for Depression, 3: Does Chirality Matter?
    Andrade C
    J Clin Psychiatry; 2017 Jun; 78(6):e674-e677. PubMed ID: 28682536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
    Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
    J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
    Medeiros da Frota Ribeiro C; Riva-Posse P
    Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
    Torjesen I
    BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
    [No Abstract]   [Full Text] [Related]  

  • 39. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.